title: KiS1--a novel monoclonal antibody which recognizes proliferating cells: evaluation of its relationship to prognosis in mammary carcinoma.
abstract: Immunohistochemical staining with a novel monoclonal antibody, KiS1, which recognizes a cell cycle-associated antigen, was investigated in 142 cases of stage I and II invasive breast carcinoma. KiS1 staining indices were compared with disease-free interval, overall survival, and post-relapse survival. Using a semi-quantitative method of assessment, we found that tumours with a high level of staining (34/142, 24 per cent) had a significantly worse prognosis than those with a low level of staining (108/142, 76 per cent). Significant correlations were found between KiS1 staining and disease-free interval (P < 0.001), overall survival (P < 0.001), and post-relapse survival (P = 0.008). A more time-consuming, quantitative method of assessment gave similar results. Cox multivariate analysis showed these results to be independent of nodal status, histological type, and grade of tumour (P = 0.01). We conclude that KiS1 is a valuable new antibody which affords useful prognostic information in breast carcinoma. As it can be used in formalin-fixed, paraffin-embedded material, it may be of particular use in the study of small lesions such as those identified in the Breast Cancer Screening Programme.
authors.affiliation: Department of Histopathology, UMDS, Guy's Hospital, London, U.K.
authors.forename: S A
authors.initials: SA
authors.lastname: Sampson
authors.forename: H
authors.initials: H
authors.lastname: Kreipe
authors.forename: C E
authors.initials: CE
authors.lastname: Gillett
authors.forename: P
authors.initials: P
authors.lastname: Smith
authors.forename: M A
authors.initials: MA
authors.lastname: Chaudary
authors.forename: A
authors.initials: A
authors.lastname: Khan
authors.forename: K
authors.initials: K
authors.lastname: Wicks
authors.forename: R
authors.initials: R
authors.lastname: Parwaresch
authors.forename: D M
authors.initials: DM
authors.lastname: Barnes
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm / Q000032:analysis*; D001943:Breast Neoplasms / Q000276:immunology* / Q000401:mortality / Q000473:pathology; D002455:Cell Division / Q000276:immunology; D004250:DNA Topoisomerases, Type II; D004268:DNA-Binding Proteins; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000032:analysis*; D009687:Nuclear Proteins / Q000032:analysis*; D000075223:Poly-ADP-Ribose Binding Proteins; D011379:Prognosis
chemical_list: D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D004268:DNA-Binding Proteins; D009363:Neoplasm Proteins; D009687:Nuclear Proteins; D000075223:Poly-ADP-Ribose Binding Proteins; D004250:DNA Topoisomerases, Type II; C000618811:TOP2A protein, human